Destiny Cosmetics

Destiny Pharma is a clinical-stage biotechnology company based in the United Kingdom that develops novel medicines to prevent life-threatening infections. The company's primary focus is on addressing antimicrobial resistance (AMR) through its proprietary XF platform, which creates drugs that kill bacteria rapidly without inducing resistance. Its lead candidate, XF-73, is a Phase 3-ready nasal gel designed to prevent post-surgical Staphylococcal infections, including MRSA. Another key asset, NTCD-M3, is a Phase 3-ready live biotherapeutic product for the prevention of Clostridioides difficile infection recurrence. Destiny Pharma is listed on the AIM market of the London Stock Exchange and maintains strategic partnerships for the development and commercialization of its pipeline.